A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel and ingesting an enteric-coated activated charcoal to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.
